Navigation Links
'Twinkle After-Effect' Can Help Retinal Patients Detect Vision Loss Quickly and Cheaply and Prevent Further Loss
Date:10/24/2007

Scientists hope to make it available online

BOSTON, Oct. 24 /PRNewswire/ -- Scientists at Schepens Eye Research Institute have discovered a simple and inexpensive way for patients with retinal and other eye disease to keep track of changes in their vision loss. In a study published in this week's PLoS One (October 24, 2007) they demonstrate that a compelling visual illusion known as the induced twinkle after-effect (TAE) can accurately identify the location and breadth of actual blind spots in people with retinal disease. The twinkle after-effect is a "twinkling" that people can see in a blind spot when they stare at a blank screen after staring at a noisy visual target such as a detuned television screen.

"Our hope is that we can make this simple technique available online or on a DVD," says Dr. Peter Bex, associate scientist at Schepens Eye Research Institute and the principal investigator of the study. "This will be particularly helpful with patients who have glaucoma, diabetic retinopathy or macular degeneration where early detection of changes in vision can impact the effectiveness of treatments."

According to Bex, many people fail to seek help when they develop blind spots in their vision, because their brains automatically compensate or "fill in" the missing information in their visual field. Since everyone has a blind spot where the optic nerve meets the retina, this perceptual "fill in" process is useful for normally sighted people, allowing them a complete visual image. "But this innate process can mask the effects of serious disorders such as diabetic retinopathy and glaucoma and keep sufferers from seeking help until the vision loss is very serious or they bump into objects they can no longer see."

The traditional gold standard method for detecting blind spots (scotomas) is very expensive and time consuming and must be done in an ophthalmologist's office. The technique known as retinal specific microperimetry i
'/>"/>

SOURCE Schepens Eye Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Retinal Hemorrhage: No More a Sure Sign of Child Abuse
2. Another feather in fish oil cap: hope against retinal degenerative diseases
3. There is light at the end of the blind tunnel: prosthetic retinal cells offer hope!
4. Software System to Improve the Function of Retinal Implants
5. One in Three Heart Attack Patients Have No Chest Pains
6. Amphetamines Help Recovery of Stroke Patients
7. Painkillers Do Not Shorten Dying Patients Lives
8. Patients With Filariasis More Prone To HIV Infection
9. Glivec - New Hope For CMC Patients
10. HIV infected patients can travel safely abroad
11. New vaccine helps allergy and asthma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...s Group on Health Recognize the Nation,s Best Heal... WASHINGTON, Dec. 2 As...and human tolls across the country, leaders at the...morial Hermann Healthcare System (Houston, TX) hav...xecutive-suite and extend throughout their organiz...
(Date:12/2/2008)...ire-FirstCall/ -- Cantel Medical Corp. (NYSE: CM...pany,s results for its first quarter ended October...ticipating in the call will be Charles M. Diker, C...heldon, Senior Vice President and CFO; and Roy K. ...h is a Cantel subsidiary. The first quarter result...
(Date:12/2/2008)...people, family gatherings, parties, and other soci...eason. Not so for those with social anxiety disord...eports the December 2008 issue of Harvard Women,s...(Vocus) December 2, 2008 -- For most people, famil... are part of the fun of the holiday season. Not so...
(Date:12/2/2008)...kinnyAndTheCity.com launches as the definitive on...and feel their best. Renowned nutritionist Tan...credited team of experts in the fields of nutritio...all together on one website to offer the most on-t...e market today - all at no cost and no calories to...
Breaking Medicine News(10 mins):Health News:Leaders at Henry Ford Health System and Memorial Hermann Healthcare System Awarded for Commitment to Creating Safer, More Transparent Environments for Patients 2Health News:Leaders at Henry Ford Health System and Memorial Hermann Healthcare System Awarded for Commitment to Creating Safer, More Transparent Environments for Patients 3Health News:Leaders at Henry Ford Health System and Memorial Hermann Healthcare System Awarded for Commitment to Creating Safer, More Transparent Environments for Patients 4Health News:Leaders at Henry Ford Health System and Memorial Hermann Healthcare System Awarded for Commitment to Creating Safer, More Transparent Environments for Patients 5Health News:Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008 2Health News:Easing Social Anxiety During the Holidays: Tips from Harvard Women's Health Watch 2Health News:SkinnyAndTheCity.com Top Experts Create the Ultimate Lifestyle Guide 2
... HIV have approximately a hundred times greater ri...he general population,// researchers at the US Nat...s were published in the March 1st online edition o...Infectious Diseases. Osteonecrosis or ‘bone d...
...entists have developed a house to help people with...ctivity and sounds a warning when it thinks there ... the Bath Institute of Medical Engineering could m...can now stay in their own homes for longer, rather...
...of new cases diagnosed with cancer among the aging...// and 2006, according to report published. It is... cases of cancer (up from 2.9 million in 2004) and...n the whole of Europe. Professor Peter Boyle, Dir...
...ducted by the scientists at Western Infirmary Epil...racetam is effective as a single therapy. This stu...as a double-blind study which had around six hundr...st two attacks of convulsions in the last year to ...
Other Medicine News:Health News:HIV-positive Individuals Have a Massively Increased Risk of Osteonecrosis 2Health News:HIV-positive Individuals Have a Massively Increased Risk of Osteonecrosis 3Health News:‘Smart House’ Developed to Monitor People With Dement 2Health News:Marked Increase of Cancer Cases Among Aging Population 2Health News:Marked Increase of Cancer Cases Among Aging Population 3Health News:Marked Increase of Cancer Cases Among Aging Population 4
(Date:12/2/2008)..., Calif., Dec. 2 TorreyPines Thera...sitive results from a 26 patient Phase II trial ev...xerostomia, or dry mouth, in patients with Sjogren... statistically significant increase in salivary fl...es: 10 mg, 15 mg, and 20 mg. These doses were safe...
(Date:12/2/2008)...Ill., Dec. 2 Horizon Therapeutics,..., today announced that two pivotal,Phase 3 trials...date, HZT-501,met all primary endpoints. HZT-501...duct containing ibuprofen and famotidine, demonstr... incidence of non-steroidal,anti-inflammatory dru...
(Date:12/2/2008)..., Md., Dec. 2 Micromet, ...y developing novel, proprietary antibodies for the...diseases, today announced that it has entered into...cing Facility (CEFF) with Kingsbridge Capital Limi...of the agreement, Kingsbridge has committed to pro...
(Date:12/1/2008)... Dec. 2 New research ha...slice computed tomography (CT) scanner in an emerg... stroke victims who receive a potentially life-sav...North Shore Medical Center (NSMC)-Salem Hospital i...ual meeting of the Radiological Society of North A...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3A tiny pinch from a z ring helps bacteria cells divide 760 1A tiny pinch from a z ring helps bacteria cells divide 760 2A tiny pinch from a z ring helps bacteria cells divide 760 3Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee 1212 1Drug Makers Withdraw Cough Cold Meds for Infants 3468 1Drug Makers Withdraw Cough Cold Meds for Infants 3468 2Drug Makers Withdraw Cough Cold Meds for Infants 3468 3European lead in reading past climates from ice cores 759 1European lead in reading past climates from ice cores 759 2European lead in reading past climates from ice cores 759 3
..., 2007 /PRNewswire-FirstCall/ -- Shire plc,announc...system),the first and only non-oral medication ap...ivity Disorder (ADHD) in children aged 6,to 12 yea...ntrol,and tolerability, according to results of a ...n Psychiatric Association (APA),annual meeting in ...
...(BUSINESS WIRE)--May 23, 2007 - Synta,Pharmaceutic...any,focused on discovering, developing, and commer...ical conditions, today announced,that survival and...ial in metastatic melanoma of the Company,s lead o...d at the annual meeting of the,American Society of...
Other Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3
...tal Camera Systems provide the advanced functional...r advanced training. Programmable, easy to activat...ed to accommodate the imaging demands of all endos...le and non-autoclavable camera heads, the new IM32...
...amera System provides easy-to-use features, auto i...e camera head construction is based on Solos durab...ystem for Microscopic Application, Domestic (MS 10...CCU) with power cord and video cables , (MS 1050-0...
...amera System provides easy-to-use features, auto i...e camera head construction is based on Solos durab...Camera System, International (GS9900-PAL) includes... cord and video cables , (GS 9905) Camera head wit...
...ers 800+ lines of resolution along with color bar ...white balance features in a user-friendly design. ...GS 9920-PAL) includes: , (GS 9923) Camera Control ...ead with 3 meter cable (10 ft.)(1/2" format CCD) ...
Medicine Products: